No headlines found.
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Business Wire (Wed, 20-Mar 4:00 PM ET)
Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference
PRNewswire (Thu, 29-Feb 4:00 PM ET)
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
PRNewswire (Wed, 28-Feb 4:00 PM ET)
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
Arcellx trades on the NASDAQ stock market under the symbol ACLX.
As of March 28, 2024, ACLX stock price declined to $69.55 with 319,251 million shares trading.
ACLX has a beta of 1.60, meaning it tends to be more sensitive to market movements. ACLX has a correlation of 0.11 to the broad based SPY ETF.
ACLX has a market cap of $3.39 billion. This is considered a Mid Cap stock.
The top ETF exchange traded funds that ACLX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
ACLX has outperformed the market in the last year with a return of +131.8%, while the SPY ETF gained +33.6%. In the last 3 month period, ACLX beat the market returning +20.8%, while SPY returned +10.1%. However, in the most recent 2 weeks ACLX has underperformed the stock market by returning -1.4%, while SPY returned +1.7%.
ACLX support price is $68.10 and resistance is $72.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACLX stock will trade within this expected range on the day.